NCT02562742 - Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection | Biotech Hunter

Enrollment

554

Participants

Timeline

Start Date

November 12, 2015

Primary Completion Date

June 12, 2017

Study Completion Date

June 12, 2017

Conditions

Hepatitis C

Interventions

DRUG

SOF

SOF 400 mg tablets administered orally once daily

DRUG

REB

REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)

Trial Locations (45)

Unknown

Ageo-shi

Bunkyō City

Chuo-shi

Fujioka-shi

Fukui-shi

Fukuoka

Hakodate-shi

Handa-shi

Ichihara-shi

Inashiki-gun

Iruma-gun

Kamogawa-shi

Karatsu-shi

Kashiwa-shi

Katsushika-ku

Kawagoe-shi

Kawasaki-shi

Kitamoto-shi

Kobe

Kodaira-shi

Kōtoku

Kurume-shi

Kyoto

Matsue

Matsuyama

Minatoku

Miyazaki

Morioka

Nagoya

Osaka

Osakasayama-shi

Saitama-shi

Sakaishi

Sapporo

Shibuya-ku

Shimotsuke-shi

Shinjuku-ku

Sumida-ku

Tagawa-shi

Tondabayashi-shi

Toyama

Toyoake-shi

Utsunomiya

Yanagawa-shi

Yokohama